Determination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents Versus Biolimus A9-eluting Stents

Launched by YONSEI UNIVERSITY · Mar 11, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at how long patients should take dual antiplatelet therapy (DAPT) after receiving two types of heart stents: the Everolimus-eluting stent and the Biolimus A9-eluting stent. DAPT is a treatment that helps prevent blood clots, and this study will use a special imaging technique called Optical Coherence Tomography (OCT) to see how well the stents are working three months after they are placed. The goal is to find out the best duration for DAPT to reduce complications related to the stents over a follow-up period of up to 10 years.

To be eligible for this trial, you need to have been part of a previous study called the DETECT-OCT study and be willing to give your consent. If you join this study, you can expect regular follow-ups to monitor your condition and the effectiveness of your treatment. It’s important to know that this trial is not yet recruiting participants, so you may need to wait before you can take part.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. patients who were enrolled in the previous DETECT-OCT study
• • 2. Patients who agreed with informed consents
• Exclusion Criteria:
• • 1. Patients who disagreed with informed consents